Evaluation of prognostic factors for dogs with synovial sarcoma: 36 cases (1986–1991)

David M. Vail From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by David M. Vail in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Barbara E. Powers From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by Barbara E. Powers in
Current site
Google Scholar
PubMed
Close
 DVM
,
David M. Getzy From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by David M. Getzy in
Current site
Google Scholar
PubMed
Close
 DVM
,
Wallace B. Morrison From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by Wallace B. Morrison in
Current site
Google Scholar
PubMed
Close
 DVM
,
Margaret C. McEntee From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by Margaret C. McEntee in
Current site
Google Scholar
PubMed
Close
 DVM
,
Deborah A. O’Keefe From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by Deborah A. O’Keefe in
Current site
Google Scholar
PubMed
Close
 DVM
,
Alan M. Norris From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by Alan M. Norris in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Stephen J. Withrow From the Department of Medical Sciences, School of Veterinary Medicine and The Comprehensive Cancer Center, Department of Human Oncology, School of Medicine, University of Wisconsin, Madison, Wl 53706 (Vail); The Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Powers, Getzy, Withrow); The School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 (Morrison); College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606 (McEntee); Department of Veterinary Clinical Medicine, University of Illinos, Urbana, IL 61801 (O’Keefe); and The Veterinary Referral Clinic of Mississauga, Mississauga, ON L4Z 1X8 Canada (Norris).

Search for other papers by Stephen J. Withrow in
Current site
Google Scholar
PubMed
Close
 DVM

Summary

Medical records of 36 dogs with synovial sarcoma confirmed by microscopic examination of h&e-stained sections of tissue were selected for retrospective analysis from dogs admitted between 1986 and 1991 to participating institutions of the Veterinary Cooperative Oncology Group. Metastasis was evident at the time of diagnosis in 8 (22%) dogs, and 15 (41%) dogs ultimately developed metastatic tumors. Median survival time for all dogs, as determined by lije-table analysis, was 17 months. For dogs that were subsequently treated and became tumor free, the median disease-free interval was 30 months. Nine dogs had previously had localized excision attempted, but all had recurrence of the tumor locally (median, 4.5 months). Of 29 dogs that underwent amputation, including the 9 with localized recurrence, 2 had tumor recurrence on the amputation stump. Most dogs had survival time and disease-free interval of > 36 months after amputation. Four dogs that had received chemotherapy for tumors of advanced clinical stages did not respond to treatment. One dog that had received locally applied radiotherapy after localized excision did not have evidence of tumor recurrence 2 years after radiotherapy. Clinical stage, histologic grade, and a positive result for tests that used cytokeratin immunohistochemical staining significantly (P < 0.05) influenced survival time and disease-free interval. Analysis of data for the study reported here suggested that histologic criteria can be an excellent predictor of dogs that are likely to have tumor recurrence after amputation and that would most likely benefit from aggressive treatment with adjuvants.

Summary

Medical records of 36 dogs with synovial sarcoma confirmed by microscopic examination of h&e-stained sections of tissue were selected for retrospective analysis from dogs admitted between 1986 and 1991 to participating institutions of the Veterinary Cooperative Oncology Group. Metastasis was evident at the time of diagnosis in 8 (22%) dogs, and 15 (41%) dogs ultimately developed metastatic tumors. Median survival time for all dogs, as determined by lije-table analysis, was 17 months. For dogs that were subsequently treated and became tumor free, the median disease-free interval was 30 months. Nine dogs had previously had localized excision attempted, but all had recurrence of the tumor locally (median, 4.5 months). Of 29 dogs that underwent amputation, including the 9 with localized recurrence, 2 had tumor recurrence on the amputation stump. Most dogs had survival time and disease-free interval of > 36 months after amputation. Four dogs that had received chemotherapy for tumors of advanced clinical stages did not respond to treatment. One dog that had received locally applied radiotherapy after localized excision did not have evidence of tumor recurrence 2 years after radiotherapy. Clinical stage, histologic grade, and a positive result for tests that used cytokeratin immunohistochemical staining significantly (P < 0.05) influenced survival time and disease-free interval. Analysis of data for the study reported here suggested that histologic criteria can be an excellent predictor of dogs that are likely to have tumor recurrence after amputation and that would most likely benefit from aggressive treatment with adjuvants.

Advertisement